Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,265 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Specific keynote: molecular therapeutics in ovarian cancer.
Mills GB, Fang X, Lu Y, Hasegawa Y, Eder A, Tanyi J, Tabassam FH, Mao M, Wang H, Cheng KW, Nakayama Y, Kuo W, Erickson J, Gershenson D, Kohn EC, Jaffe R, Bast RC Jr, Gray J. Mills GB, et al. Among authors: jaffe r. Gynecol Oncol. 2003 Jan;88(1 Pt 2):S88-92; discussion S93-6. doi: 10.1006/gyno.2002.6692. Gynecol Oncol. 2003. PMID: 12586094 Review. No abstract available.
Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer.
Mills GB, Eder A, Fang X, Hasegawa Y, Mao M, Lu Y, Tanyi J, Tabassam FH, Wiener J, Lapushin R, Yu S, Parrott JA, Compton T, Tribley W, Fishman D, Stack MS, Gaudette D, Jaffe R, Furui T, Aoki J, Erickson JR. Mills GB, et al. Among authors: jaffe r. Cancer Treat Res. 2002;107:259-83. doi: 10.1007/978-1-4757-3587-1_12. Cancer Treat Res. 2002. PMID: 11775454 Review.
Lysophosphatidic acid is a bioactive mediator in ovarian cancer.
Fang X, Schummer M, Mao M, Yu S, Tabassam FH, Swaby R, Hasegawa Y, Tanyi JL, LaPushin R, Eder A, Jaffe R, Erickson J, Mills GB. Fang X, et al. Among authors: jaffe r. Biochim Biophys Acta. 2002 May 23;1582(1-3):257-64. doi: 10.1016/s1388-1981(02)00179-8. Biochim Biophys Acta. 2002. PMID: 12069836 Review.
Impact of vessel maturation on antiangiogenic therapy in ovarian cancer.
Lu C, Thaker PH, Lin YG, Spannuth W, Landen CN, Merritt WM, Jennings NB, Langley RR, Gershenson DM, Yancopoulos GD, Ellis LM, Jaffe RB, Coleman RL, Sood AK. Lu C, et al. Among authors: jaffe rb. Am J Obstet Gynecol. 2008 Apr;198(4):477.e1-9; discussion 477.e9-10. doi: 10.1016/j.ajog.2007.12.028. Am J Obstet Gynecol. 2008. PMID: 18395047 Free PMC article.
Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.
Lu C, Shahzad MM, Moreno-Smith M, Lin YG, Jennings NB, Allen JK, Landen CN, Mangala LS, Armaiz-Pena GN, Schmandt R, Nick AM, Stone RL, Jaffe RB, Coleman RL, Sood AK. Lu C, et al. Among authors: jaffe rb. Cancer Biol Ther. 2010 Feb;9(3):176-82. doi: 10.4161/cbt.9.3.10635. Epub 2010 Feb 16. Cancer Biol Ther. 2010. PMID: 20009575 Free PMC article.
1,265 results